Viridian Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Viridian Therapeutics, retaining the price target of $46.00.

Rami Katkhuda’s rating is based on several promising developments within Viridian Therapeutics’ pipeline, particularly the progress of VRDN-003. The completion of enrollment in the pivotal REVEAL program, which assesses the safety and efficacy of VRDN-003 in both active and chronic Thyroid Eye Disease (TED), is a significant milestone. The studies not only exceeded their enrollment targets but also have the potential to lead to a Biologics License Application (BLA) submission by the end of next year if the upcoming data is positive. This progress, combined with the drug’s advantageous properties, such as its formulation as a low-volume, self-administered autoinjector, positions VRDN-003 favorably in the TED market.
Additionally, the recent granting of a composition of matter patent for VRDN-003, valid until 2041, strengthens Viridian’s intellectual property portfolio. The anticipation of a BLA submission for veligrotug, another promising candidate, with a potential commercial launch in mid-2026, further supports the Buy rating. The Breakthrough Therapy Designation granted by the FDA underscores veligrotug’s rapid and significant clinical benefits, enhancing its differentiation from existing therapies. These factors collectively indicate a strong growth potential for Viridian Therapeutics, justifying the Buy recommendation.

According to TipRanks, Katkhuda is a 5-star analyst with an average return of 30.7% and a 53.33% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Dianthus Therapeutics, and Mineralys Therapeutics, Inc..

In another report released today, Wedbush also maintained a Buy rating on the stock with a $40.00 price target.